122,153 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 122,153 shares of the company's stock, valued at approximately $2,844,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.24% of Spyre Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in shares of Spyre Therapeutics in the fourth quarter worth approximately $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Spyre Therapeutics by 85.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 48,981 shares of the company's stock worth $1,140,000 after buying an additional 22,540 shares in the last quarter. Woodline Partners LP lifted its stake in shares of Spyre Therapeutics by 33.5% in the fourth quarter. Woodline Partners LP now owns 352,680 shares of the company's stock worth $8,210,000 after buying an additional 88,424 shares in the last quarter. Squarepoint Ops LLC lifted its stake in shares of Spyre Therapeutics by 79.7% in the fourth quarter. Squarepoint Ops LLC now owns 15,231 shares of the company's stock worth $355,000 after buying an additional 6,754 shares in the last quarter. Finally, RTW Investments LP lifted its stake in shares of Spyre Therapeutics by 11.2% in the fourth quarter. RTW Investments LP now owns 3,621,996 shares of the company's stock worth $84,320,000 after buying an additional 363,636 shares in the last quarter. Institutional investors own 80.39% of the company's stock.

Analyst Ratings Changes

SYRE has been the topic of several analyst reports. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Leerink Partnrs upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, April 8th. Wolfe Research began coverage on shares of Spyre Therapeutics in a research note on Tuesday, March 18th. They set an "outperform" rating and a $27.00 target price on the stock. Leerink Partners began coverage on shares of Spyre Therapeutics in a research note on Tuesday, April 8th. They set an "outperform" rating and a $45.00 target price on the stock. Finally, Wedbush restated an "outperform" rating and set a $65.00 target price on shares of Spyre Therapeutics in a research note on Monday, May 5th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $53.40.

Spyre Therapeutics Trading Up 3.3%

SYRE stock traded up $0.55 during midday trading on Friday, reaching $17.17. 76,563 shares of the company's stock traded hands, compared to its average volume of 613,543. Spyre Therapeutics, Inc. has a 52-week low of $10.91 and a 52-week high of $40.26. The stock has a market cap of $1.03 billion, a P/E ratio of -2.30 and a beta of 2.78. The stock's 50-day moving average is $14.20 and its 200 day moving average is $19.62.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.02. As a group, research analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).